News

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...
HSBC Trims Amgen (AMGN) Price Target, Maintains Buy Rating
Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc. ...
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
Milestone Pharmaceuticals' recent $52.5 million equity raise was poorly timed and dilutive, but it ensures its survival even ...
Zacks Investment Research on MSN2d
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...
Life Science Leader2d
Why So Many Biotech Launches Miss Expectations, And How To Fix It
More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...
How Is The Market Feeling About Regeneron Pharmaceuticals?
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
Investing Snacks3d
Regeneron’s Risky Rendezvous with Melanoma
Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...
Japan Is Down, But Fujifilm Stands Out
Fujifilm delivered strong FY2025 results, driven by progress on VISION2030 and a diversified business mix. Read why FUJIY ...